Figure 3.
Use of any rate controlling therapies in patients randomized to early rhythm control (left panel) and usual care (right panel) in the EAST-AFNET 4 population. This display includes antiarrhythmic drugs with rate controlling properties, namely amiodarone, dronedarone, propafenone, and sotalol. The use of these medications often obviates the need for additional rate-controlling medication, explaining the lower use of beta blockers, calcium channel antagonists, or digoxin shown in A.